Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darrick Carter

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Immunohorizons|April 26, 2025
Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvantSasha E Larsen, Maham Rais, Valerie A Reese, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complexAgapito Castilleja, Darrick Carter, Clay L Efferson, et al.
Frontiers in Tropical Diseases|November 1, 2024
An assessment of a GMP schistosomiasis vaccine (SchistoShield<sup>®</sup>)Jiho Kim, Jenn Davis, Jinhee Lee, et al.
Scientific Reports|April 18, 2019
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer TherapyRagan Pitner, Jiho Kim, Jenn Davis-Bergthold, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeuticMaximilian Richter, Roma Yumul, Kamola Saydaminova, et al.
Molecular Therapy. Methods & Clinical Development|June 2, 2015
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicinMaximilian Richter, Roma Yumul, Hongjie Wang, et al.
Vaccine|March 20, 2016
Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigenSusan L Baldwin, Will Roeffen, Susheel K Singh, et al.
Msphere|December 14, 2018
Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific AntibodiesRie Nakajima, Medalyn Supnet, Algis Jasinskas, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaquesInes Beyer, Hua Cao, Jonas Persson, et al.
Biochemistry|May 23, 2002
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancerDarrick Carter, John F Douglass, Charisa D Cornellison, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Immunohorizons|April 26, 2025
Characterizing TLR4 agonist EmT4™ as an anti-Mycobacterium tuberculosis vaccine adjuvantSasha E Larsen, Maham Rais, Valerie A Reese, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2002
Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complexAgapito Castilleja, Darrick Carter, Clay L Efferson, et al.
Frontiers in Tropical Diseases|November 1, 2024
An assessment of a GMP schistosomiasis vaccine (SchistoShield<sup>®</sup>)Jiho Kim, Jenn Davis, Jinhee Lee, et al.
Scientific Reports|April 18, 2019
Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer TherapyRagan Pitner, Jiho Kim, Jenn Davis-Bergthold, et al.
Molecular Therapy. Methods & Clinical Development|April 13, 2016
Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeuticMaximilian Richter, Roma Yumul, Kamola Saydaminova, et al.
Molecular Therapy. Methods & Clinical Development|June 2, 2015
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicinMaximilian Richter, Roma Yumul, Hongjie Wang, et al.
Vaccine|March 20, 2016
Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigenSusan L Baldwin, Will Roeffen, Susheel K Singh, et al.
Msphere|December 14, 2018
Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific AntibodiesRie Nakajima, Medalyn Supnet, Algis Jasinskas, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaquesInes Beyer, Hua Cao, Jonas Persson, et al.
Biochemistry|May 23, 2002
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancerDarrick Carter, John F Douglass, Charisa D Cornellison, et al.
Pageof 11